Abstract
As drug development for Th2-driven diseases such as atopic dermatitis (AD) and asthma expands into advanced modalities—including bispecific antibodies and ADCs—reliable in vivo models are increasingly essential for translational preclinical evaluation. Join our upcoming webinar to explore Biocytogen’s target-humanized mouse models for AD and asthma, which enable direct in vivo evaluation of human biologics without the need for surrogate antibodies. These models cover key therapeutic targets including IL-4Rα, TSLP, OX40, IL-33, and IL-13, and support studies across multiple therapeutic modalities.
Key highlights
✅ Model selection and study design strategies for mechanism-driven drug development
✅ Insights into emerging asthma and AD targets using target-humanized disease models
✅ In vivo case studies across mAbs, bispecifics, and ADCs
Speaker’s Information:
Dr Zhen Chen received his PhD in Biology from Nanjing University, where his research focused on neurodevelopment and regeneration, building a strong foundation in genetics and humanized animal disease models. Dr. Chen currently serves as the head of the autoimmune pharmacology department at Biocytogen and has managed over 100 preclinical projects with multiple pharmaceutical partners in successful IND and NDA findings in both China and the United States.
